Paul B Manning bought $2.1M of Taysha Gene Therapies (TSHA)
Executed May 30 2025, disclosed Jun 3 2025, 4 days later.
Over the 21 trading sessions from the disclosed entry session (Jun 3 2025), the stock returned -16.5% (delay-adjusted); from the execution session (May 30 2025), -14.4%. Derived: entry at the session's open, exit at the close 20 sessions later.
Paul B Manning (Director) filed 3 Form 4 reports in the trailing twelve months (2 purchases, 1 sale, 1 filed past the two-business-day deadline), most often in Candel Therapeutics, Inc. (CADL). Across 2 priced purchase filings, the average 21-session return was +36.0% from execution and +33.7% from disclosure (delay-adjusted; derived). The largest single filing was $17.5M of VRCA (4,126,142 sh across 2 lots, as filed), executed Nov 25 2025.
Healthcare · Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→